The robust anti-glioma effect displayed by EphA3-CAR T cells, particularly in our in vivo models, aligns with the therapeutic efficacy seen in other studies targeting surface antigens in solid tumors, including lung cancer and melanoma.18 This evidence concerns the gene EPHA3 and glioma.